Am J Transplant, Volume 17, Suppl 3 Archives - Page 165 of 181 - ATC Abstracts

2017 American Transplant Congress
Incidence of Donor-Specific Anti-HLA Antibodies in Non-HLA Sensitized Patients Given Tacrolimus Once or Twice Daily During the First Two Years Post-Transplantation.
N. Kamar, V. Hajj, I. Ferrandiz, E. Younes, L. Esposito, A. Hébral, A. Del Bello.
Department of Nephrology and Organ Transplantation, Toulouse University Hospital, Toulouse, France
Donor-specific anti-HLA antibody (DSA)-mediated rejection (AMR) is a main cause of graft loss after kidney transplantation. Non-adherence is a risk factor for AMR and graft…
2017 American Transplant Congress
Evaluation of Vancomycin Resistant Enterococcus (VRE) Colonization and Infection Rate in Adult Liver Transplant Patients.
E. Aldag,¹ G. Fouth,¹ R. Pedersen,¹ L. Fehrenbacher,^1,2 A. Sahajpal,¹ V. Gunabushanam,¹ D. Kramer.¹
¹Aurora St Luke's Medical Center, Milwaukee; ²Concordia University Wisconsin School of Pharmacy, Mequon
Background: VRE infections are associated with higher morbidity and mortality among patients undergoing liver transplantation.Objective: The primary outcomes are to look at VRE infection rate…
2017 American Transplant Congress
AAV8 Delivery of TIMP-1 Prevents Hepatocyte Apoptosis After Liver Ischemia/Reperfusion Injury.
S. Duarte, P. Matian, M. Miller, R. Busuttil, A. Coito.
Dumont-UCLA Transplant Center, Los Angeles
Matrix metalloproteinase-9 (MMP-9) is a key mediator of leukocyte migration across vascular barriers in hepatic ischemia/reperfusion injury (IRI). Tissue inhibitor of metalloproteinase-1 (TIMP-1) is the…
2017 American Transplant Congress
Nuclear Co-Repressor Complex Inhibition Reverses Benefit of HDAC2 Deletion in Renal Ischemia.
D. Aufhauser Jr,¹ D. Murken,¹ Z. Wang,¹ A. Samanta,² G. Ge,¹ T. Bhatti,³ P. Cole,⁴ J. Kalin,⁴ W. Hancock,^2,3 M. Levine.^1,5
¹Surgery, University of Pennsylvania, Philadelphia, PA; ²Pathology, University of Pennsylvania, Philadelphia, PA; ³Pathology, Children's Hospital of Philadelphia, Philadelphia, PA; ⁴Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, MD; ⁵Surgery, Children's Hospital of Philadelphia, Philadelphia, PA
Introduction: Class I histone/protein deacetylases (HDACs) 1 and 2 bear >85% protein sequence homology and conventionally are thought to have similar function via occupancy in…
2017 American Transplant Congress
Model to Predict Prolonged Delayed Graft Function (DGF) Following Kidney Transplantation from Deceased Donor with Acute Kidney Injury (AKI Tx).
R. Heilman,¹ B. Smith,² C. Johnson,¹ H. Khamash,¹ K. Reddy,¹ W. Kremers,² B. Kaplan.¹
¹Mayo Clinic, Phoenix, AZ; ²Mayo Clinic, Rochester, MN
Background Our aim is to develop a model to predict prolonged DGF following AKI Tx.Methods AKI Tx (donor terminal Cr>/=2) from 2003 to 2016 were…
2017 American Transplant Congress
Renal Transplant Outcomes in Primary FSGS Compared with Other Recipients: A National Review of the Irish Transplant Registry.
S. Cormican,¹ C. Kennedy,^1,2 P. O'Kelly,¹ B. Doyle,³ A. Dorman,³ P. Conlon.^1,2
¹Nephrology, Beaumont Hospital, Dublin, Ireland; ²Medicine, Royal College of Surgeons, Dublin, Ireland; ³Pathology, Beaumont Hospital, Dublin, Ireland
Primary focal segmental glomerular sclerosis (p-FSGS) raises specific peri-transplant concerns, one of which is disease recurrence (r-FSGS). We aimed to compare transplant outcomes in patients…
2017 American Transplant Congress
Renal Transplant Patient Outcomes Following Plasmapheresis, Thymoglobulin, and Rituximab Induction for High Risk DSA Positive Recipients.
E. Lessmann,¹ M. Moaddab,¹ M. Manson,¹ A. Ram,² R. Kerman,² P. Jindra.²
¹Pharmacy, CHI St. Luke's Health Baylor St. Luke's Medical Center, Houston, TX; ²Immune Evaluation Laboratory, Baylor College of Medicine, Houston, TX
Background: Kidney transplantation is associated with improved survival and quality of life relative to dialysis for patients with end-stage renal disease (ESRD). Patients who are…
2017 American Transplant Congress
Incidence of Acute Rejection and Donor Specific Antibodies in Low-Immunological Risk Patients Treated by Tacrolimus and Mycophenolic Acid with or without Induction Therapy.
O. Marion,¹ A. Del Bello,¹ I. Ferrandiz,¹ L. Esposito,¹ N. Congy,² A.-L. Hebral,¹ N. Kamar.¹
¹Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France; ²Laboratory of Histocompatibility, CHU Rangueil, Toulouse, France
The need for using induction therapy in de novo non-HLA sensitized kidney-transplant patients receiving tacrolimus-based therapy is a matter of debate. The aims of this…
2017 American Transplant Congress
Risk Factors and Outcomes of Intracardiac Thrombosis During Orthotopic Liver Transplantation.
W. Al-Darzi, M. El-Atrache, F. Georgie, O. Sadiq, S. Singla, C. Fernandez, R. Pompa, D. Galusca, A. Yoshida, S.-M. Jafri.
Henry Ford Hospital, Detroit, MI
Introduction: Intracardiac Thrombosis (ICT) during Orthotopic Liver Transplantation (OLT) is an uncommon event associated with high mortality. The incidence of ICT during OLT is estimated…
2017 American Transplant Congress
De-Novo Portal Vein Thrombosis After Adult-to-Adult Living Donor Liver Transplantation (LDLT) Does Not Impact on Long-Term Outcome.
I. Linares,¹ N. Goldaracena,¹ R. Rosales,¹ L. De La Maza,¹ J. Echeverri,¹ M. Kaths,¹ D. Kollman,¹ N. Selzner,² S. McCluskey,³ G. Sapisochin,¹ L. Lilly,² P. Greig,¹ M. Bhat,² A. Ghanekar,¹ M. Cattral,¹ I. McGilvray,¹ D. Grant,¹ M. Selzner.¹
¹Department of Surgery, Multi-Organ Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada; ²Department of Medicine, Multi-Organ Transplant Program, Toronto General Hospital University Health Network, Toronto, ON, Canada; ³Department of Anesthesiology, Toronto General Hospital, University Health Network, Toronto, ON, Canada
Portal vein thrombosis(PVT) after deceased donation has been widely described as a liver transplant complication that can lead to graft failure, high morbidity and mortality.…